Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

Cancer Research

Volumn 73, Issue 2, 2013, Pages 483-489

  Li, Yingming ^c   Chan, Siu Chiu ^c   Brand, Lucas J ^a,c   Hwang, Tae Hyun ^b,c   Silverstein, Kevin A T ^d   Dehm, Scott M ^c,e  

^a Graduate Program in Microbiology Immunology and Cancer Biology   (United States)

^b Biostatistics and Bioinformatics Core ^*  (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ENZALUTAMIDE;

ADVANCED CANCER; ANDROGEN RECEPTOR GENE; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG RESPONSE; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84872534568     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3630     Document Type: Article

References (20)

1. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011;17: 1649-57.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364: 1995-2005.
3. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367: 1187-97.
4. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375: 1437-46.
5. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011;18:R183-96.
6. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate AR target genes and support aberrant prostate cancer cell growth independent of the canonical AR nuclear localization signal. J Biol Chem 2012;287: 19736-49.
7. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011;6:e19059.
8. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011;6:e27970.
9. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al.Anovel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69: 2305-13.
10. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69: 16-22.
11. Watson PA, Chen YF, BalbasMD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107: 16759-65.
12. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011; 71: 2108-17.
13. Li Y, Hwang TH, Oseth L, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012;31: 4759-67.
14. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61: 2892-8.
15. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68: 5469-77.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal Biochem 1987;162: 156-9.
17. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19: 575-86.
18. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-62.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-50.
20. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration- resistant prostate cancer. J Clin Oncol 2010;28: 1496-501.